ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET
Rhea-AI Summary
ANI Pharmaceuticals (NASDAQ: ANIP) has announced its plans to release second quarter 2024 financial results on Tuesday, August 6, 2024, before the market opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Nikhil Lalwani, President and CEO, and Stephen P. Carey, SVP of Finance and CFO, will lead the call.
Investors and interested parties can access the call toll-free at 800-245-3047 using the Conference ID 4619279. A live webcast and replay will be available on the company's website under the 'Investors' section. For those unable to attend, a replay will be accessible for two weeks by dialing 800-753-5212 with the same access code.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ANIP gained 2.08%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:
| Date | Tuesday, August 6, 2024 |
| Time | 8:30 a.m. ET |
| Toll free (U.S.) | 800-245-3047 |
| Conference ID | 4619279 |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-753-5212 and entering access code 4619279.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint. For more information, visit www.anipharmaceuticals.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
When will ANI Pharmaceuticals (ANIP) release its Q2 2024 financial results?
What time is ANI Pharmaceuticals' (ANIP) Q2 2024 earnings call scheduled for?
How can investors access ANI Pharmaceuticals' (ANIP) Q2 2024 earnings call?
Who will be hosting ANI Pharmaceuticals' (ANIP) Q2 2024 earnings call?
